What is Quantum BioPharma Ltd's earnings per share (EPS)?

Quantum BioPharma Ltd (QNTM) reported diluted earnings per share of $-8.20 for fiscal year 2025. This represents a 37.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Quantum BioPharma Ltd Financials

QNTM

Source SEC Filings (10-K/10-Q) Data as of Dec 31, 2025 Currency USD FYE December

This page shows Quantum BioPharma Ltd (QNTM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial health score pending refresh

We are recalculating Quantum BioPharma Ltd's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$-8.20

YoY+37.5%

Quantum BioPharma Ltd earned $-8.20 per diluted share (EPS) in fiscal year 2025. This represents an increase of 37.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$1.9M

YoY-68.2%

5Y CAGR-35.8%

Quantum BioPharma Ltd held $1.9M in cash against $1.3M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

QNTM Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	$19K+103.9%	$9K-9.8%	$10K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	-$23.6M+33.1%	-$35.3M-11.0%	-$31.8M
EPS (Diluted)	$-8.20+37.5%	$-13.12	$-29.93-4237.7%	$-0.69+28.9%	$-0.97+58.9%	$-2.36

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$4.7M+51.4%	-$9.8M-11.7%	-$8.7M	N/A	-$4.0M-19.8%	-$3.4M-60.3%	-$2.1M
EPS (Diluted)	N/A	$-1.25+61.3%	$-3.23+8.5%	$-3.53	N/A	$-4.37-5362.5%	$-0.08+97.7%	$-3.43

QNTM Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$11.2M-34.8%	$17.1M-2.0%	$17.5M-54.5%	$38.4M-39.0%	$63.0M+50.0%	$42.0M
Current Assets	$6.5M-46.2%	$12.1M+8.7%	$11.1M-37.9%	$17.9M-61.1%	$45.9M+71.0%	$26.9M
Cash & Equivalents	$1.9M-68.2%	$6.0M+117.5%	$2.8M-83.8%	$17.0M-51.8%	$35.3M+101.2%	$17.5M
Inventory	$52K-55.5%	$117K	$0	N/A	N/A	$0
Accounts Receivable	N/A	N/A	N/A	$374K-25.3%	$501K+210.5%	$161K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$6.1M-9.3%	$6.7M+46.3%	$4.6M-42.0%	$7.9M-10.9%	$8.8M+56.1%	$5.7M
Current Liabilities	$6.1M-9.3%	$6.7M+46.3%	$4.6M-41.7%	$7.8M-10.0%	$8.7M+55.9%	$5.6M
Long-Term Debt	$1.3M+110.1%	$619K	$0-100.0%	$38K-71.0%	$131K+65.6%	$79K
Total Equity	$5.1M-51.1%	$10.4M-19.1%	$12.9M-57.7%	$30.5M-43.6%	$54.1M+49.1%	$36.3M
Retained Earnings	-$198.3M-15.2%	-$172.1M-9.0%	-$157.9M-9.5%	-$144.2M-14.3%	-$126.2M-38.8%	-$90.9M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$11.2M-21.1%	$14.2M-7.5%	$15.3M+2.8%	$14.9M-13.1%	$17.1M-10.0%	$19.0M+24.8%	$15.2M	N/A
Current Assets	$6.5M-30.7%	$9.3M-9.7%	$10.3M+4.1%	$9.9M-17.6%	$12.1M-12.9%	$13.8M+38.1%	$10.0M	N/A
Cash & Equivalents	$1.9M+327.3%	$446K-70.2%	$1.5M-57.4%	$3.5M-41.3%	$6.0M+92.2%	$3.1M-5.6%	$3.3M+148.6%	$1.3M
Inventory	$52K-32.8%	$78K+1.0%	$77K-18.1%	$94K-19.9%	$117K	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$6.1M-8.8%	$6.6M-49.8%	$13.2M+28.1%	$10.3M+54.9%	$6.7M+81.4%	$3.7M-27.0%	$5.0M	N/A
Current Liabilities	$6.1M-8.8%	$6.6M-49.8%	$13.2M+28.1%	$10.3M+54.9%	$6.7M	N/A	$5.0M	N/A
Long-Term Debt	$1.3M-34.2%	$2.0M+1.6%	$1.9M+78.7%	$1.1M+75.7%	$619K	N/A	N/A	N/A
Total Equity	$5.1M-32.0%	$7.5M+266.7%	$2.0M-54.8%	$4.5M-56.6%	$10.4M-32.0%	$15.3M+50.4%	$10.2M-11.4%	$11.5M
Retained Earnings	-$198.3M-1.5%	-$195.3M-2.8%	-$189.9M-5.1%	-$180.7M-5.0%	-$172.1M-3.2%	-$166.8M-2.3%	-$162.9M	N/A

QNTM Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$8.2M-19.8%	-$6.9M+36.5%	-$10.8M+61.8%	-$28.3M-36.6%	-$20.7M-8.4%	-$19.1M
Capital Expenditures	N/A	$0	$0-100.0%	$114K	$0	$0
Free Cash Flow	N/A	-$6.9M+36.5%	-$10.8M+61.9%	-$28.4M-37.1%	-$20.7M-8.4%	-$19.1M
Investing Cash Flow	-$2.0M-29.9%	-$1.5M-457.7%	-$270K-102.2%	$12.1M+4407.4%	$269K-95.9%	$6.5M
Financing Cash Flow	$6.1M-47.5%	$11.6M+471.6%	-$3.1M-51.1%	-$2.1M-105.4%	$38.2M+58.1%	$24.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$306K+82.2%	-$1.7M+11.7%	-$1.9M+54.3%	-$4.3M-409.8%	-$836K+75.9%	-$3.5M-470.6%	-$606K+69.3%	-$2.0M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$351K-14.1%	$408K+130.0%	-$1.4M-0.8%	-$1.4M-208.5%	$1.2M+135.9%	-$3.5M-569.2%	$738K+3434.3%	-$22K
Financing Cash Flow	$1.4M+441.0%	$261K-79.7%	$1.3M-58.8%	$3.1M+27.0%	$2.5M-63.4%	$6.7M+265.3%	$1.8M+224.4%	$569K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

QNTM Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	-77.3%-12.1pp	-65.2%+22.4pp	-87.6%
Return on Assets	N/A	N/A	N/A	-61.5%-5.4pp	-56.0%+19.7pp	-75.8%
Current Ratio	1.07-0.7	1.80-0.6	2.43+0.1	2.28-3.0	5.28+0.5	4.82
Debt-to-Equity	0.25+0.2	0.06+0.1	0.000.0	0.000.0	0.000.0	0.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-63.2%+413.9pp	-477.1%-284.1pp	-193.0%	N/A	-26.2%+6.7pp	-32.9%-14.7pp	-18.2%
Return on Assets	N/A	-33.5%+30.3pp	-63.8%-5.1pp	-58.8%	N/A	-21.1%+0.9pp	-22.0%	N/A
Current Ratio	1.07-0.3	1.41+0.6	0.78-0.2	0.96-0.8	1.80	N/A	1.99	N/A
Debt-to-Equity	0.250.0	0.26-0.7	0.95+0.7	0.24+0.2	0.06-0.2	0.24-0.3	0.49	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Medicinova MNOV

$67.9M

Abvc Biopharma Inc ABVC

$37.7M

Pmv Pharmaceuticals, Inc. PMVP

$66.1M

Applied Therapeutics APLT

$14.9M

Precision Biosciences DTIL

$236.3M

Frequently Asked Questions

How much debt does Quantum BioPharma Ltd have?

As of fiscal year 2025, Quantum BioPharma Ltd (QNTM) had $1.9M in cash and equivalents against $1.3M in long-term debt.

What is Quantum BioPharma Ltd's operating cash flow?

Quantum BioPharma Ltd (QNTM) generated -$8.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Quantum BioPharma Ltd's total assets?

Quantum BioPharma Ltd (QNTM) had $11.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What is Quantum BioPharma Ltd's current ratio?

Quantum BioPharma Ltd (QNTM) had a current ratio of 1.07 as of fiscal year 2025, which is considered adequate.

What is Quantum BioPharma Ltd's debt-to-equity ratio?

Quantum BioPharma Ltd (QNTM) had a debt-to-equity ratio of 0.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Quantum BioPharma Ltd's cash runway?

Based on fiscal year 2025 data, Quantum BioPharma Ltd (QNTM) had $1.9M in cash against an annual operating cash burn of $8.2M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.